β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma

Haematologica

Volumn 96, Issue 2, 2011, Pages 253-261

  Anand, Mona ^a   Lai, Raymond ^a   Gelebart, Pascal ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

catenin; Alk+alcl; Npm alk; Stat3

Indexed keywords

ALPHA TUBULIN; ANAPLASTIC LYMPHOMA KINASE; BETA CATENIN; HISTONE DEACETYLASE 1; NUCLEOPHOSMIN; SMALL INTERFERING RNA; STAT3 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL FRACTIONATION; CELL GROWTH; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; LUCIFERASES; LYMPHOMA, LARGE-CELL, ANAPLASTIC; NUCLEAR PROTEINS; PHOSPHORYLATION; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

EID: 79551623658     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.027086     Document Type: Article

References (37)

1. Delsol G FB, Muller-Hermelink HK, Campo E, Jaffe ES, Gascoyne RD, Stein H, et al. Anaplastic Large Cell Lymphoma (ALCL), ALK-Positive. Lyon: IARC, 2008.
2. Armstrong F, Duplantier MM, Trempat P, Hieblot C, Lamant L, Espinos E, et al. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene. 2004;23(36):6071-82.
3. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene. 2002;21(7):1038-47.
4. Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood. 2007;110(7):2259-67.
5. Dien Bard J, Gelebart P, Anand M, Zak Z, Hegazy SA, Amin HM, et al. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am J Pathol. 2009;175(2):825-34.
6. Turner SD, Yeung D, Hadfield K, Cook SJ, Alexander DR. The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms. Cell Signal. 2007;19(4): 740-7.
7. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosminanaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3- kinase/Akt antiapoptotic signaling pathway. Blood. 2000;96(13):4319-27.
8. Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, et al. Role of phosphatidylinositol 3-kinase- Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 2001;61(5):2194-9.
9. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005;11(6):623-9.
10. Khoury JD, Medeiros LJ, Rassidakis GZ, Yared MA, Tsioli P, Leventaki V, et al. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res. 2003;9(10 Pt 1):3692-9.
11. Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K, et al. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene. 2004;23 (32):5426-34.
12. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127 (3):469-80.
13. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 2006;281(32):22429-33.
14. Staal FJ, Clevers HC. WNT signalling and haematopoiesis: a WNT-WNT situation. Nat Rev Immunol. 2005;5(1):21-30.
15. Ding Y, Shen S, Lino AC, Curotto de Lafaille MA, Lafaille JJ. Beta-catenin stabilization extends regulatory T cell survival and induces anergy in nonregulatory T cells. Nat Med. 2008;14(2):162-9.
16. Chung EJ LM, Lee S, Hwang S-G, Rubin JS, Trepel JB. Posttranslational control of betacatenin signaling regulates peripheral blood lymphocyte activation. ASH. Atlanta, Georgia, 2005.
17. Chung EJ, Hwang SG, Nguyen P, Lee S, Kim JS, Kim JW, et al. Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood. 2002;100 (3):982-90.
18. Tomita M, Kikuchi A, Akiyama T, Tanaka Y, Mori N. Human T-cell leukemia virus type 1 tax dysregulates beta-catenin signaling. J Virol. 2006;80(21):10497-505.
19. Groen RW, Oud ME, Schilder-Tol EJ, Overdijk MB, ten Berge D, Nusse R, et al. Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies. Cancer Res. 2008;68(17):6969-77.
20. Gelebart P, Anand M, Armanious H, Peters AC, Dien Bard J, Amin HM, et al. Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood. 2008;112(13):5171-9.
21. Kajiguchi T, Chung EJ, Lee S, Stine A, Kiyoi H, Naoe T, et al. FLT3 regulates betacatenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells. Leukemia. 2007;21(12):2476-84.
22. Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, et al. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem. 2007;282(15):11221-9.
23. Coluccia AM, Vacca A, Dunach M, Mologni L, Redaelli S, Bustos VH, et al. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J. 2007;26(5): 1456-66.
24. Kajiguchi T, Lee S, Lee MJ, Trepel JB, Neckers L. KIT regulates tyrosine phosphorylation and nuclear localization of betacatenin in mast cell leukemia. Leuk Res. 2008;32(5):761-70.
25. Pulford K, Lamant L, Morris SW, Butler LH, Wood KM, Stroud D, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)- ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997;89(4):1394-404.
26. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA. 2008;105(52): 20852-7.
27. Yan S, Zhou C, Zhang W, Zhang G, Zhao X, Yang S, et al. beta-Catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma. Cancer Lett. 2008;271(1):85-97.
28. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev. 2007;17(1):45-51.
29. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2004;101(9):3118-23.
30. Khan NI, Bradstock KF, Bendall LJ. Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Br J Haematol. 2007;138(3):338-48.
31. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA. 2004;101(16):6122-7.
32. Bard JD, Gelebart P, Anand M, Amin HM, Lai R. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. Leukemia. 2008; 22(8):1595-603.
33. Cussac D, Greenland C, Roche S, Bai RY, Duyster J, Morris SW, et al. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood. 2004; 103(4):1464-71.
34. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol. 2002;168(1):466-74.
35. Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPMALK in ALK+ anaplastic large-cell lymphoma. Blood. 2006;108(8):2796-803.
36. Colomba A, Courilleau D, Ramel D, Billadeau DD, Espinos E, Delsol G, et al. Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas. Oncogene. 2008;27(19):2728-36.
37. Ambrogio C, Voena C, Manazza AD, Martinengo C, Costa C, Kirchhausen T, et al. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res. 2008;68(21):8899-907.